tbuckley/cabot-search huggingface dataset:
Lines Missing
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Typhoid Fever
Authors: E. J. McCollum
Journal: JAMA (1896)

<h3>AS SEEN AND TREATED FORTY YEARS AGO COMPARED WITH THE TREATMENT OF THE SAME DISEASE AT THE PRESENT TIME.</h3><h3>To the Editor:</h3> —When attending the lectures of Prof. J. K. Mitchell, in the Jefferson, 1853, I remember of his theory that typhoid fever and other fevers were caused by fungi. He wrote a book on the subject. Should any member of the class of 1853 read these lines they will bear me out in these statements. He asked me in the green room what was the duty of a physician when called to a patient with typhoid fever. I gave him in reply the verbatim statement he gave in his lectures, that he should act in the capacity of a pilot or steersman on a boat to steer the craft clear of dangerous breakers. This was found to be a difficult thing to do. We found the tongue heavily coated,
Almost a reality: prediction of drug effects on human cancers
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cost analysis of screening according to ECCO guidelines for prevention of opportunistic infections in infliximab-treated ibd patients
Authors: A. Metz, T. Elliott, B. Hull, J. Duncan, M. Sastrillo, M. Smith, J. D. Sanderson, P. M. Irving
Journal: Gut (2011)

<h3>Introduction</h3> We previously reported that our practice of screening for and prevention of opportunistic infections (OI9s) in at risk IBD patients was not in line with ECCO recommendations.12 In this study, we aimed first to seek evidence of OI9s in our historical cohort of infliximab (IFX)-treated patients who had not been screened according to recommendations and second, to analyse the cost-effectiveness of screening of, and prophylaxis as required for tuberculosis (TB) and hepatitis B (hep B) in IFX-treated patients. <h3>Methods</h3> An audit of consecutive patients treated with IFX (2005–2009) was conducted and occurrence of OIs and duration of IFX were recorded. A cost-minimisation analysis was performed using clinical decision analytic modelling to assess cost outcome of screening and prevention versus not screening and prevention. Model branch probabilities were obtained from a Medline search. The cost perspective was the health sector. Hospital admissions were based on Healthcare Resource Group (HRG4) codes. <h3>Results</h3> There were no OI9s identified in 92 IBD patients treated with a median of 21 months of IFX. For 1000 hypothetical Crohn9s patients in a western European population, the model predicted 15 screened patients required isoniazid prophylaxis, with 0.5 unscreened patients admitted to hospital with TB. There was an incremental cost for screening of £39.50/patient for CXR alone, or £125.60 for CXR combined with an interferon release assay. Conversely, there was a cost saving for screening in Southern Europe (£12/patient). For Hepatitis B in the Western European population, the model predicted 35.7 screened patients required lamivudine prophylaxis, whereas in the unscreened group, 2 patients reactivated with hepatitis, 3 patients with liver failure, and one required a transplant. There was a cost saving of £32/patient for screening. <h3>Conclusion</h3> There were no significant OI9s identified in this audit of IFX-treated IBD patients despite failure to screen according to ECCO guidelines. The cost analysis model demonstrates cost saving for hepatitis B screening because of the significant cost of hepatitis B reactivation. In the southern European population there is a cost benefit for TB screening due to a high rate of latent TB whereas in the western European population, there is an incremental cost for screening because of a lower risk of TB reactivation there. This cost should be balanced against the risk of death due to TB reactivation (reported in Southern but not Western Europe).3
An open-label, cohort study of grazoprevir/elbasvir combination therapy for patients with genotype 1b chronic hepatitis C after liver or kidney transplantation
Authors: Teng-Yu Lee, Ping-Chin Lai, Long-Bin Jeng, Yu Tung-Min, Ming-Ju Wu, Cheng-Hsu Chen, Shang-Feng Tsai, Shao-Bin Cheng, Shengshun Yang
Journal: Journal of Hepatology (2020)
Abstract 2315: Alteration of tumor metabolism by CD4+ T cells leads to TNF-α-dependent intensification of oxidative stress and tumor cell death
Authors: Zhichun Ding, Tsadik Habtetsion, Gang Zhou
Journal: Cancer Research (2019)

Abstract The inhibitory effects of cancer on T cell metabolism have been well established, but the metabolic impact of immunotherapy on tumor cells is poorly understood. Here, we developed a CD4+ T cell-based adoptive immunotherapy protocol that was curative for mice with implanted colorectal tumors. By conducting metabolic profiling on tumors, we show that adoptive immunotherapy profoundly altered tumor metabolism, resulting in glutathionedepletion and accumulation of reactive oxygen species (ROS) in tumor cells. We further demonstrate that T cell-derived tumor necrosis factor alpha (TNF-α) can synergize with chemotherapy to intensify oxidative stress and tumor cell death in an NADPH (nicotinamide adenine dinucleotide phosphate hydrogen) oxidase-dependent manner. Reduction of oxidative stress, by preventing TNF-α-signaling in tumor cells or scavenging ROS, antagonized the therapeutic effects of adoptive immunotherapy. Conversely, provision of pro-oxidants after chemotherapy can partially recapitulate the antitumor effects of T cell transfer. These findings imply that reinforcing tumor oxidative stress represents an important mechanism underlying the efficacy of adoptive immunotherapy. Citation Format: Zhichun Ding, Tsadik Habtetsion, Gang Zhou. Alteration of tumor metabolism by CD4+ T cells leads to TNF-α-dependent intensification of oxidative stress and tumor cell death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2315.
Pancreatic Society of Great Britain and Ireland
Authors: Christopher Guest, I Terry, A Ran, Ermon- Tay Or (depaoritnew, M Larvin, A Mayer, M Mcmahon, S Macgowan, P Broe
Journal: Gut (1987)

Geotrge's Hospitall, Lon1doni) Appropriate intraperitoncal antiproteinase chemo- therapy for ANP may include the use of oligopeptide inhibitors of bacterial origin as these agents are capable of inactivating pancreatic proteinases of different specifici- ties in compilex with (xL-maicroglobulin.'We h.lve studied the eftfect of administering these agents, singularly and in combination, in peritoneal lavage (PL) fluid at concentra- tions of' 0(4 mM on the survival times of rates with enterokinase-induced ANP.' PL was routinely commenced 12 hours after induction of ANP and consisted of 2x20 ml aliquots of' Ringer's solution at 370C administered over 20 minutes, and repeated at one and three hours after the first lavage.Rats were randomly allocated into four experimentcal groups after ANP.Results:TPIN-1c.tllp)tuill X 12 cs 5+--;-TI'Pl.-AititiiIi) 10 2 (_' 6 + I'l;statiunal '<0:0S in noTPL:t'.;T>().L Rincr s These results show that PL with a btalanced physiological salt solution stairting 12 hours after ANP significantly reduced mortality and prolonged mrean survival of' experi- mentail animrals.The addition of specific antiproteinases to the PL conf'erred no additional survival benefit.'Ihese findings do not support the intraperitonacal adminis- traution of' antiprotcinaises in the therapy of clinical ANP. Rteferesices
JUVENILE TABES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma
Authors: N. Lewis, L. S. Rosen, C. Rocha Lima, J. L. Marshall, S. F. Jones, R. B. Cohen, L. Kunkel, S. Stewart, H. A. Burris
Journal: Journal of Clinical Oncology (2008)

3023 Background: RAV12 is a high affinity, internalizing, chimeric IgG1 monoclonal antibody that binds RAAG12, a novel primate-restricted N-linked carbohydrate epitope present on multiple cell-surface proteins. RAAG12 is expressed on normal non-keratinizing epithelia, particularly those of GI origin, and is not expressed on human cardiovascular, endocrine, hematolymphatic, neuromuscular, and central nervous tissues. IHC studies demonstrated diffuse membrane staining on > 90% of human colorectal, gastric, and pancreatic adenocarcinoma samples. In vitro, RAV12 kills tumor cells by oncosis, facilitates ADCC and CDC, and modulates growth factor receptor signaling. Methods: A phase I dose-escalation safety and pharmacokinetics (PK) trial was conducted in pts with recurrent adenocarcinoma. RAV12 was administered initially weekly x 4, then by fractionated dosing twice or thrice weekly. Thirty-three patients were treated in the dose escalation segment of the trial in the following cohorts: 0.3 mg/kg qw (6), 1.0 mg/kg qw (8), 1.5 mg/kg qw (7); 0.5 mg/kg biw (3), 0.75 mg/kg biw (3), and 0.5 mg/kg tiw (6). Twenty (20) pts were enrolled in an MTD cohort expansion at 0.75 mg/kg biw. Thirty-three (33) pts had colorectal, 8 pancreatic, 7 gastroesophageal, 2 lung, 1 breast, 1 ovarian, and 1 biliary tract cancer. Responses were evaluated on day 42. Results: Preliminary analysis demonstrated dose-dependent PK. PK in pts treated with fractionated dosing demonstrated that Cmax was significantly reduced while AUC was maintained compared to weekly dosing. Two clinical syndromes associated with drug administration were observed with weekly dosing, but ameliorated with fractionated dosing: abdominal cramping pain with diarrhea, and asymptomatic, self-limited, reversible increases of LFTs. One pt with advanced pancreatic cancer, had a > 50% reduction in CA19–9, with TTP > 5 months. One pt with colorectal cancer experienced a durable partial remission, with TTP > 8 months. Conclusions: RAV12 has activity in recurrent adenocarcinoma. Side effects have included abdominal discomfort and abnormal LFTs. The recommended dose and schedule is 0.75 mg/kg biw. Experience from the MTD cohort expansion will be analyzed to further define the safety, PK, immunogenicity, and efficacy profiles. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Raven biotechnologies Amgen, Bristol-Myers Squibb, Genentech, Pfizer, Roche, Sanofi Genentech, Pfizer, Raven biotechnologies Amgen, Bristol-Myers Squibb, Genentech, Pfizer, Roche, sanofi-aventis
The continued use of retracted, invalid scientific literature
Authors: M. P. Pfeifer
Journal: JAMA (1990)

Little is known about the ultimate scientific fate of retracted, invalid literature. We identified 82 completely retracted articles by electronic and manual methods and measured their subsequent use in the scientific literature by performing citation analysis. After retraction, these studies were cited, for support of scientific concepts, 733 times. Comparison with a control group revealed that retraction reduces subsequent citation by approximately 35%. There was no evidence that small, obscure journals, non-US journals, or non-US authors were disproportionately responsible for these citations. Although, after retraction, US authors accounted for a smaller percentage of citations, they continued to be the single greatest source. Several possible reasons why invalid information continues to be used were identified. These included a dearth of available information on retracted works; inconsistency in retraction format, terminology, and indexing; and an apparent lack of sufficient attention to manuscripts by some authors and editors. (<i>JAMA</i>. 1990;263:1420-1423)
Complications of insulin infusion pump therapy
Authors: J. J. Bending
Journal: JAMA (1985)

<h3>In Reply.—</h3> Adverse effects of testicular hyperthermia are well known and were described in the COUNCIL REPORT as well as in my reply to Dr Levine's letter.<sup>1</sup>Such effects from occupational exposure to heat are not established. The article by Rachootin and Olsen was published after our article on physical forces was submitted. Had we known of this article, it would have been referenced, although the information in it is not sufficient to change the implications (not conclusions) that occupational exposures to heat are not likely to have significant adverse effects on male reproductive functions. The article by Rachootin and Olsen did not define "heat exposures," and the authors properly did not draw any conclusions about effects of occupational exposures to heat in males. As to the possibility of adverse effects on human female fertility, the same article reported an association between women with fertility problems and exposure to
Injuries Associated With Horseback Riding—United States, 1987 and 1988
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Presidential Address
Authors: CHESTER S. KEEFER
Journal: Annals of Internal Medicine (1961)

Special Article1 July 1961Presidential AddressCHESTER S. KEEFER, M.D., F.A.C.P.CHESTER S. KEEFER, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-55-1-158 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTonight you are being admitted to Fellowship in the American College of Physicians, so I hasten to extend to you a very sincere welcome.We, who have been Fellows for some time, have learned to appreciate the intellectual value of such a Fellowship. We know that your experience will duplicate ours. We are proud to have you as Fellows because we recognize that the College will grow only through the medium of new members who have met the high standards for admission and election. We know that you will bring to the College new ideas, new inspirations, and new strengths.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, MassachusettsReceived for publication May 19, 1961.Delivered before the Convocation of the Forty-second Annual Session of The American College of Physicians, Miami Beach, Florida, May 8-12, 1961.Requests for reprints should be addressed to Chester S. Keefer, M.D., 65 East Newton Street, Boston 18, Mass. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByFactors of Responsibility in the Care of Medical EmergenciesThe Image of the American PhysicianJ. R. E. 1 July 1961Volume 55, Issue 1Page: 158-162KeywordsFellowships Issue Published: 1 July 1961 PDF DownloadLoading ...
From the Food and Drug Administration
Authors: Stuart L. Nightingale
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New horizons for intravenous feeding
Authors: S. J. Dudrick
Journal: JAMA (1971)

Dr. Rhoads: We are deeply honored to receive the Joseph Goldberger Award, memorializing as it does a man whose contributions in helping to elucidate the metabolic significance of the vitamin B complex, initiated a wave of important discoveries in the field of nutrition. The award has been enhanced by the reputations and contributions of the several scientists who have been recipients in the past. Dr. Dudrick and I wish to acknowledge frankly our great indebtedness to our associates, past and present, in studies of surgical nutrition. These include Dr. I. S. Ravdin, who was one of the first surgeons to recognize the relevance of nutritional studies to the progress of surgical science, and who stayed with the field almost exclusively through the 1930s and early 1940s; to Dr. Harry M. Vars, who joined the Harrison Department of Surgical Research in 1936 as a biochemist and who has devoted his entire
2-Year Follow-up of a Phase II Study on Catumaxomab as Part of a Multimodal Approach in Primarily Resectable Gastric Cancer
Authors: C. Bokemeyer, K. Ridwelski, D. Atanackovic, D. Arnold, E. Wöll, M. Büchler, C. Krüger, C. Schuhmacher
Journal: Annals of Oncology (2012)
Will expansion of the NHS abroad benefit UK patients? No
Authors: A. M. Pollock
Journal: BMJ (2012)

The new NHS mandate calls for hospitals to set up more profit making branches abroad. <b>Philip Leonard</b> (doi:10.1136/bmj.e8493) says this will bring new revenue to the cash strapped service, but <b>Allyson Pollock</b> says that promoting trade in healthcare over universal access benefits no one
Reply
Authors: M.I. WHITE, D.MCEWAN JENKINSON, D.H. LLOYDf
Journal: British Journal of Dermatology (1987)

Journal Article Reply Get access M.I. WHITE, M.I. WHITE Department of Dermatology, Aberdeen Royal Infirmary Search for other works by this author on: Oxford Academic Google Scholar D.MCEWAN JENKINSON, D.MCEWAN JENKINSON Moredun Institute, Gilmerton, Edinburgh Search for other works by this author on: Oxford Academic Google Scholar D.H. LLOYDf D.H. LLOYDf Royal Veterinary College London, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 117, Issue 5, 1 November 1987, Pages 671–672, https://doi.org/10.1111/j.1365-2133.1987.tb07510.x Published: 01 November 1987
Fight against fraud tracks 'miracle cures'
Authors: K. Simmons
Journal: JAMA (1985)

For every physician unable to cure the incurable, there are countless charlatans who claim they can. With asparagus oil, coffee enemas, and ground diamond dust, they claim to "cure" cancer. For arthritis, there are extracts of the green-lipped mussel, cow manure poultices, and radon gas treatments from uranium mines. And for the aging, there are innumerable devices and gadgets touted to eliminate wrinkles, restore hair, and cure senility. It's all part of what a 1984 Congressional report called a "$10 billion a year scandal." The federal government now is enlisting state, local, and private agencies to combat it. The FDA is one of several federal agencies charged with policing health fraud; its role is to enforce the Food, Drug, and Cosmetics Act of 1938. With sanctions ranging from regulatory (or warning) letters to seizures, injunctions, and civil and even criminal proceedings, the FDA has perhaps the broadest authority of all